The stock of BioAtla Inc (NASDAQ: BCAB) has increased by 6.36 when compared to last closing price of 1.18.Despite this, the company has seen a loss of -12.24% in its stock price over the last five trading days. globenewswire.com reported 2024-12-16 that Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS)
Is It Worth Investing in BioAtla Inc (NASDAQ: BCAB) Right Now?
The 36-month beta value for BCAB is at 1.03. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BCAB is 39.02M, and currently, shorts hold a 10.21% of that float. The average trading volume for BCAB on December 19, 2024 was 1.19M shares.
BCAB’s Market Performance
BCAB’s stock has seen a -12.24% decrease for the week, with a -16.33% drop in the past month and a -27.03% fall in the past quarter. The volatility ratio for the week is 9.13%, and the volatility levels for the past 30 days are at 9.09% for BioAtla Inc The simple moving average for the past 20 days is -17.20% for BCAB’s stock, with a -37.71% simple moving average for the past 200 days.
Analysts’ Opinion of BCAB
JMP Securities, on the other hand, stated in their research note that they expect to see BCAB reach a price target of $17. The rating they have provided for BCAB stocks is “Mkt Outperform” according to the report published on September 15th, 2022.
Credit Suisse gave a rating of “Neutral” to BCAB, setting the target price at $5 in the report published on May 05th of the previous year.
BCAB Trading at -29.17% from the 50-Day Moving Average
After a stumble in the market that brought BCAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.78% of loss for the given period.
Volatility was left at 9.09%, however, over the last 30 days, the volatility rate increased by 9.13%, as shares sank -14.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.50% lower at present.
During the last 5 trading sessions, BCAB fell by -11.19%, which changed the moving average for the period of 200-days by -55.28% in comparison to the 20-day moving average, which settled at $1.5165. In addition, BioAtla Inc saw -48.98% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCAB starting from MCBRINN SYLVIA, who purchase 4,000 shares at the price of $2.33 back on Dec 26 ’23. After this action, MCBRINN SYLVIA now owns 15,125 shares of BioAtla Inc, valued at $9,320 using the latest closing price.
SHORT JAY M PHD, the Chief Executive Officer of BioAtla Inc, purchase 50,000 shares at $2.14 during a trade that took place back on Dec 20 ’23, which means that SHORT JAY M PHD is holding 1,439,283 shares at $106,910 based on the most recent closing price.
Stock Fundamentals for BCAB
Current profitability levels for the company are sitting at:
- -6.79 for the present operating margin
- 0.93 for the gross margin
The net margin for BioAtla Inc stands at -6.44. The total capital return value is set at -2.02. Equity return is now at value -139.06, with -76.61 for asset returns.
Currently, EBITDA for the company is -122.24 million with net debt to EBITDA at 0.65. When we switch over and look at the enterprise to sales, we see a ratio of 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.11.
Conclusion
In conclusion, BioAtla Inc (BCAB) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
